H.C. Wainwright has reiterated a neutral rating on Biohaven Pharmaceuticals (NYSE: BHVN) while maintaining a $10 price target, citing valuation concerns despite the stock's recent gains.
The firm's stance contrasts with other analysts who have adjusted their outlooks following Biohaven's 25.6% surge over the past week to $16.95, according to InvestingPro data. Raymond James maintained a strong buy rating but lowered its target to $30, while RBC Capital raised its target to $23. TD Cowen also reiterated a buy rating with a $30 target.
Biohaven's valuation remains a key point of contention. The company trades above fair value, classifying it among overvalued stocks tracked by InvestingPro, though its current ratio stands at 4.73, indicating liquid assets exceed short-term obligations.
The company's near-term focus includes the global licensing and collaboration agreement with SK Biopharmaceuticals, centered on the Kv7 ion channel platform and its lead asset, opakalim (BHV-7000). The asset is in Phase 2/3 development for focal epilepsy. Under the deal, Biohaven receives $400 million in cash, with $350 million paid at closing and $50 million due one year later. Additional milestones of up to $150 million and tiered royalties in the mid-teens to low twenties on U.S. net sales are also included. Outside the U.S., mid-single-digit royalties apply.
SK Biopharmaceuticals assumes legacy obligations from Knopp Biosciences, including up to $245 million in milestone payments and mid-single-digit worldwide royalties. The transaction remains subject to HSR and other antitrust clearances.
Biohaven's clinical development timelines include topline results from the RISE3 study, expected in the second half of 2026. The company also announced the promotion of David Pirman to Executive Vice President and Head of Discovery within its discovery unit.
